The global antibody drug conjugate market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The increasing geriatric population, rising prevalence of various types of cancer , and increased government investments in pharmaceutical research and development activities for more advanced cancer drugs and therapeutics are the key factors driving the global antibody drug conjugate market. More than 100 clinical trials for ADCs are currently underway. Companies are requesting label expansion for currently approved products. For instance, in Jan 2021, Enhertu, which was previously approved for breast cancer, has now been approved in the United States for the treatment of locally advanced or metastatic HER2-positive gastric cancer.
A full report of Wooden Decking Market is available at:https://orionmarketreports.com/global-antibody-drug-conjugate-market/92810/
Increased R&D activities are expected to fuel the growth of the global antibody-drugdrug conjugates market. For instance, in December 2020, ADC Therapeutics SA, a late-stage biotechnology company focused on oncology, announced the latest clinical data from its two leading projects, Loncastuximab-Tesirine (Lonca) and Camidanlumab-Tesirine (Cami), at the 62nd yearly session of the American Culture of Hematology (ASH) 2020. LoncastuximabTesirine is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against human Cluster of Differentiation (CD)19 and conjugated to a pyrrolobenzodiazepine (PBD) dimeric cytotoxin via a linker. CamidanlumabTesirin is an antibody drug conjugate (ADC) composed of a monoclonal antibody that binds to CD25 and is conjugated to the pyrrolobenzodiazepine (PBD) dimer payload tesirin.
Looking towards the high demand for antibody-drug conjugate key manufacturers of the antibody-drug conjugate are adopting several market growth strategies such as mergers & acquisitions, partnerships, and new product launches among others to meet the growing demand for dental biomaterials of dental consumables.For instance, in October 2020 Gilead completed its acquisition of Immunomedics, Inc. for approximately $ 21 billion. Gilead was able to gain access to Immunomedics’ ADC portfolio as a result of this acquisition. At the time of the acquisition, Immunomedics already had one commercialized ADC product, Trodelvy, as well as multiple products in clinical trials.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Drugs
- By Mechanism Of Action
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- F. Hoffman-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Seattle Genetics Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Antibody Drug Conjugate Market Report by Segment
By Drugs
- Adcetris
- Kadcyla
By Mechanism of Action
- CD30 Antibodies
- HER2 Antibodies
By Application
- Breast Cancer
- Lymphoma
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
